Skip to Content

Processa Pharmaceuticals Inc PCSA

Morningstar Rating
$2.37 +0.10 (4.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PCSA is trading at a 67% discount.
Price
$2.28
Fair Value
$4.84
Uncertainty
Extreme
1-Star Price
$85.62
5-Star Price
$4.46
Economic Moat
Lfcfc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCSA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.27
Day Range
$2.272.46
52-Week Range
$2.0418.00
Bid/Ask
$2.40 / $2.43
Market Cap
$4.04 Mil
Volume/Avg
166,036 / 157,612

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
15

Valuation

Metric
PCSA
Price/Earnings (Normalized)
Price/Book Value
0.41
Price/Sales
Price/Cash Flow
Price/Earnings
PCSA

Financial Strength

Metric
PCSA
Quick Ratio
8.31
Current Ratio
9.57
Interest Coverage
Quick Ratio
PCSA

Profitability

Metric
PCSA
Return on Assets (Normalized)
−94.07%
Return on Equity (Normalized)
−106.30%
Return on Invested Capital (Normalized)
−107.28%
Return on Assets
PCSA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQgfrzklnNmsy$570.1 Bil
VRTX
Vertex Pharmaceuticals IncJrbnpknmmFcyhz$108.0 Bil
REGN
Regeneron Pharmaceuticals IncDpbysknpWvyfspx$105.6 Bil
MRNA
Moderna IncGjmyptcckBxmb$40.8 Bil
ARGX
argenx SE ADRLnvbxrcxKfmr$23.5 Bil
BNTX
BioNTech SE ADRMwhtpftXjw$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncZgnqnpdJyhtlc$18.8 Bil
BMRN
Biomarin Pharmaceutical IncGvcmffpkTbbdg$16.5 Bil
RPRX
Royalty Pharma PLC Class AQjvqryfkzhLcwnhp$13.6 Bil
INCY
Incyte CorpHlchqmlrtJkcpm$12.8 Bil

Sponsor Center